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Endometrial cancer (EC) is the most frequent of the invasive tumors of the female genital tract. Although usually detected in
its initial stages, a 20% of the patients present with advanced disease. To date, no characterized molecular marker has been
validated for the diagnosis of EC. In addition, new methods for prognosis and classification of EC are needed to combat this
deadly disease. We thus aimed to identify new molecular markers of EC and to evaluate their validity on endometrial
aspirates. Gene expression screening on 52 carcinoma samples and series of real-time quantitative PCR validation on 19
paired carcinomas and normal tissue samples and on 50 carcinoma and noncarcinoma uterine aspirates were performed to
identify and validate potential biomarkers of EC. Candidate markers were further confirmed at the protein level by
immunohistochemistry and Western blot. We identified ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4,
P4HB, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2 and DCN as differentially expressed in ECs.
Furthermore, the differential expression of these biomarkers in primary endometrial tumors is correlated to their expression
level in corresponding uterine fluid samples. Finally, these biomarkers significantly identified EC with area under the receiver-
operating-characteristic values ranging from 0.74 to 0.95 in uterine aspirates. Interestingly, analogous values were found
among initial stages. We present the discovery of molecular biomarkers of EC and describe their utility in uterine aspirates.
These findings represent the basis for the development of a highly sensitive and specific minimally invasive method for
screening ECs.
Endometrial cancer (EC) is the most frequent of the inva-
sive tumors of the female genital tract and the fourth most
common in women in western countries.1 The crude inci-
dence of EC in the European Union range from 13 to 24
new cases per 100,000 women per year and a mortality rate
of 4–5 cases per 100,000 per year. It is estimated that the
lifetime risk of developing EC is 1.7–2%.2 In the United
States, about 40,100 new cases of EC have been estimated in
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2008 with 7,470 estimated deaths.1 Age-standardized inci-
dence rates continue to rise in most developed countries.
Uterine cancer usually occurs after menopause and is
usually detected in its initial stages by presentation of dis-
ease-related symptoms, including unusual vaginal bleeding
or discharge, trouble urinating, pelvic pain and pain dur-
ing intercourse. Unfortunately, at the time of diagnosis,
20% of the patients present myometrial invasion and/or
lymph node affectation, which are main indicators of an
advanced disease, related to poor prognosis and decrease
in survival rate. The standard treatment for EC varies
depending on the stage of the disease. Primary treatment
usually consists on staging surgery including hysterectomy,
bilateral adnexectomy and pelvic and/or paraaortic lymph-
adenectomy, although there exist other options as hor-
mone therapy and radiotherapy. Although EC is tradition-
ally considered as an early diagnosis/good prognosis type
of cancer, there is clearly room for improvement. An ideal
scenario is to achieve diagnosis at Stage I where the 5-
year survival rate ranges up to 95%. In addition, new
Figure 1. Hierarchical clustering of 236 (166 upregulated and 70 downregulated) differentially expressed genes between normal endometrial
tissue and cancer tissue using as thresholds the p value and then fold change. Among the cancer tissues, there are 38 samples from
endometrioid endometrial carcinomas (EECs) and 14 Type II carcinomas with different histotypes. Upregulation is indicated in red, downregulation
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methods for prognosis and classification of EC are needed
to combat this deadly disease.3
Focusing on early detection, there is a necessity for
screening methods with high sensitivity and specificity. To
date, no characterized molecular marker has been validated
for the diagnosis of EC. In addition, current methods of
diagnosing EC often create discomfort to the patient and
sometimes rely on subjective interpretation of visual images.
Methods routinely used in the clinic for diagnosing EC
include biopsy and/or transvaginal ultrasound. The final
diagnosis of EC is usually done by pathology examination
of an endometrial aspirate (20–30%) and by hysteroscopic-
guided biopsy (70–80%). The rate of success diagnosis with
hysteroscopy is over 90%, with false positives in the case
of precursor lesions of the endometrial adenocarcinoma
(hyperplasias with atypia); endometrial polyps that present
a non-negligible degree of malignancy (0–4.8%) and must
be removed although asymptomatic or benign appearance
or in the case of diffuse forms of endometrial adenocarci-
nomas that are difficult to differentiate from an endome-
trial hyperplasia.
In our work, we aimed to identify new molecular
markers of EC and to evaluate their validity on endome-
trial aspirates. For this, we first identified and validated
new robust biomarkers of EC on hysterectomy tissue sam-
ples. We next evaluated whether gene expression profiles
Table 1. Differential gene expression of endometrial cancer biomarkers in primary tumor when compared to control values
HUGO
gene




value Location Type(s) Cancer Plasma/Serum Urine Uterus
ACAA1 Acetyl-coenzyme A acyltransferase 1 1.26 0.11 Cytoplasm Enzyme x
AP1M2 Adaptor-related protein complex 1,
mu 2 subunit
1.71 0.11 Cytoplasm Transporter
CGN Cingulin 1.79 0.22 Plasma
membrane
Other x
DCN Decorin 2.55 0.06 Extracellular
space
Other x






extracellular matrix protein 2
1.22 0.08 Extracellular
space
Other x x x x
EPS8L2 EPS8-like 2 1.34 0.20 Unknown Other x x
FASTKD1 FAST kinase domains 1 1.71 0.06 Unknown Other
GMIP GEM interacting protein 1.42 0.05 Unknown Enzyme x
IKBKE Inhibitor of kappa light
polypeptide gene enhancer in
B-cells, kinase epsilon
1.37 0.17 Cytoplasm Kinase x x







1.90 0.13 Cytoplasm Enzyme x x x x
PHKG2 Phosphorylase kinase,
gamma 2 (testis)
1.34 0.09 Unknown Kinase
PPFIBP2 PTPRF interacting protein, binding
protein 2 (liprin beta 2)
1.52 0.11 Nucleus Phosphatase x





RASSF7 Ras association (RalGDS/AF-6)
domain family (N-terminal)
member 7
1.94 0.07 Unknown Other
RNF183 Ring finger protein 183 1.73 0.19 Unknown Other
SIRT6 Sirtuin (silent mating type
information regulation 2 homolog)
6 (S. cerevisiae)
1.27 0.15 Nucleus Enzyme x
SOCS2 Suppressor of cytokine signaling 2 1.69 0.06 Cytoplasm Other x x
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on uterine aspirates efficiently mirror that of paired tissue
samples. We finally confirmed the validity of these bio-
markers on uterine aspirates to differentially classify carci-
noma and control samples. The objective was to set up
the basis for the development of a test that could be
applied for the screening of risk groups of patients, to
develop a reliable tool to ameliorate the sensitivity and




Tumor samples were obtained from patients who underwent
surgery for EC in the Department of Gynecological Onco-
logy at the Vall d’Hebron University Hospital. Control tissue
was obtained from nonaffected regions of endometrial tissue
from the same patients. The protocol was previously
approved by the Institutional Review Board, and informed
consent was obtained from all of the patients involved in
our study. During preparation of the specimens, care was
taken to macroscopically dissect the carcinoma away from
any adjacent myometrium. Samples were immediately frozen
at 80 until processed for RNA extraction and gene
expression analysis.
Endometrial aspirates were collected with the help of a
Cornier pipelle, after complete informed consent was
obtained from all patients. The aspirate (uterine fluid) was
immediately transferred to an eppendorf tube containing 500
ll of a RNA preserving solution (RNA later, Ambion). The
sample was centrifuged, and the pellet containing a represen-
tative population of cells from the uterine cavity was further
processed for RNA extraction.
Microarray analysis
Total RNA was extracted with the RNeasy mini kit (Qiagen,
Hilden, Germany), following the instructions provided by the
manufacturer. Microarrays for gene expression were designed
by the Tethys algorithm using the ENSEMBL database. Cy3-
and Cy5-labeled aRNA was produced using the Message-
Amplification kit by Ambion. Microarray hybridization was
performed at 60C and 17-hr hybridization time according to
Agilent indications. Initial raw data were obtained using an
Agilent DNA Microarray Scanner (G2505B) and Agilent
acquisition software (Feature Extraction Software).
The mean fold change or M values can be ranked based
on their probability of being different from 0, according to
the absolute value of the regularized t-statistic,4 which uses
a Bayesian framework to derive a modified and improved
t-Student statistics. To make fold change–based selection,
the mean M distribution was used. This distribution is
adjusted to a normal distribution, and an iterative process
is used to define the mean M numbers that are outside the
distribution. The cutoff is chosen as n times the standard
deviations (r) from the mean. This method generates a
robust mean and standard deviation and allows to dynami-
cally adjusting the cutoff value to the noise distribution of
the data. Typically, values with mean FC > 3r or mean FC
< 3r of the sample data distribution were selected.
An indirect analysis comparison, where the expression
levels of particular biomarkers in tumor samples, was com-
pared to a reference RNA pool obtained from a group of
over 20 cell lines (melanoma, lung cancer, ovarian cancer, co-
lon cancer and several noncancer cell lines). The expression
level of particular genes in the normal samples (controls) was
compared to the same reference pool, and final expression
fold changes between tumor and normal endometrial tissue
were generated in silico eliminating the reference pool.
Real-time quantitative PCR
Quality tests (Bioanalyzer) were performed before the analy-
sis of gene expression by Taqman technology for the selected
markers of EC. Real-time quantitative PCR (RT-qPCR) was
performed following Applied Biosystem standard protocol for
the 7900HT system.
RT-qPCR validation on uterine aspirates was performed
with multiplex technology. Briefly, wells of the microfluidic
card contain Applied Biosystems fluorogenic 50 nuclease
assays that detect the real-time amplification of the array
selected targets. Relative levels of gene expression are deter-
mined from the fluorescence data generated during PCR
using the ABI PRISMV
R
7900HT Sequence Detection System
(7900HT SDS) Relative Quantification software.
Data analysis was made using the comparative DDCt
method of relative quantification. Differentially expressed
genes were confirmed by thorough statistical analysis using a
modified T-test.
Relative quantity (RQ) is the relative amount of RNA for a
specific gene present on the tumor samples referred to the
amount present on the control sample for the same gene. To
calculate the RQ, the Ct values of each gene were normalized
with respect to the Ct of the endogenous gene to get the delta
Ct. The formula 2(deltaCt) was used to calculate the RQ.
A number of endogenous genes can be used as a control
for normalization as well as other controls for normalization.
We have tested four different housekeeping genes as possible
endogenous genes for normalization purposes: 18S, B2M,
PFN-1 and POLR2A. Finally, POLR2A was the most stable
gene from all of them (data not shown), and all the calcula-
tions and statistics were done using it as endogenous. Its
expression level was similar to the genes questioned in our
test, different to 18S whose expression was quiet high com-
pared to the genes selected for the test.
M1M ROC
The area under the curve (AUC) values was calculated based
on a receiver-operating-characteristic (ROC) analysis to eval-
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Western blot and Immunohistochemistry
For immunohistochemistry validation, tissue microarrays
(TMAs) were constructed at the Pathology Department of the
Vall d’Hebron University Hospital. Representative areas from 70
paraffin-embedded carcinomas (56 endometrioid, six serous pap-
illary, one mucinous, four clear cell carcinomas and three carcino-
sarcomas) and 11 non-neoplastic endometria (four atrophic, three
proliferative, one secretory endometrial and three hyperplasias)
were carefully selected and marked on individual paraffin blocks.
Two tissue cores of 1 mm in diameter were obtained from each
paraffin block and were precisely arrayed in a new paraffin block.
Sections of 5 lm were obtained from all TMA paraffin blocks.
The protocol was approved by the Institutional Review Board,
and informed consent was obtained from all of the patients.
P4HB, PPP1R16A and EPS8L2 were detected by the indirect im-
munoperoxidase assay with citrate buffer, pH 7.3, for antigen re-
trieval. Sections were incubated with a primary antibodies against
P4HB (LS-C38385; Lifespan Biosciences, Seattle, WA) and
PPP1R16A (MaxPab polyclonal antibody; Cat# H00084988-B01,
Abnova, Taipei, Taiwan) for 1 hr at room temperature using a
dilution 1:500 and 1:100, respectively, and EPS8L2 (MaxPab; Cat#
H00064787-B01, Abnova) overnight at 1:100 dilution. Thereafter,
sections were incubated with peroxidase-conjugated goat anti-
mouse immunoglobulin (EnVision Dual System, DAKO,
Glostrup, Denmark). Endogenous peroxidase activity was
quenched with 3% H2O2. Sections were washed, and reactions
were developed with diaminobenzidine, followed by counterstain-
ing with hematoxylin. Semiquantitative evaluation of PH4B was
performed by three independent investigators, scoring the inten-
sity of the stained and the percentage of positive cells.
P4HB protein levels were analyzed by Western blot in
four different paired samples of EC and their respective adja-
cent normal endometrial, as described.5 P4HB levels were
examined with the antibody LS-C38385 (1:250), and actin
was used as loading control.
Results
Identification of new robust molecular markers of EC
A total of 52 human ECs and three preneoplastic atypical
hyperplasias were processed for the analysis of gene expres-
sion using Agilent Technology. The gene expression levels for
each of these samples, detected with more than 25,000
probes, were compared to a control mean expression value
obtained from ten different normal endometria. Human sam-
ples included all histological types and tumor grades in a rep-
resentative manner to identify a diagnostic tool applicable to
a complete panel of ECs (73% endometrioid, 10% serous and
17% other Type II ECs; Supporting Information Table 1).
Supervised hierarchical clustering of 236 genes (166 upregu-
lated and 70 downregulated) clearly differentiated between
tumor and nontumor samples (Fig. 1).
A first round of candidate gene selection, based on statis-
tical data mining, rendered a list of 100 potential biomarkers
for further confirmation by RT-qPCR. The differential candi-
date gene expression levels between normal endometrial tis-
sue and ECs were assessed in an independent series of sam-
ples including paired samples of primary Type I and Type II
ECs and the adjacent normal endometrium from 17 patients.
We also validated the biomarkers onto two samples of nor-
mal endometrium and two samples of endometrioid
Figure 2. Analysis of gene expression correlation of the identified endometrial carcinoma markers in primary tumors and uterine fluids.
Lineal regression and coefficient of determination R2 when comparing the RT-PCR data obtained from primary tumor carcinomas and
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endometrial tumor tissue obtained by biopsy-guided hyster-
oscopy (Supporting Information Table 2). This additional
validation on biopsies aimed to prove whether the bio-
markers were suitable to discriminate ECs from normal tis-
sue on samples obtained through the standard procedure
used on a day-to-day basis. Both with primary carcinomas
and biopsies, we found a good correlation between cDNA
microarray data and RT-qPCR expression levels when com-
paring tumor tissue and normal endometrium, with a valida-
tion of 80% of genes with a p value less than 0.01 (data not
shown).
Among the validated genes, a second round of candidate
gene selection refined the list to 20 potential biomarkers for
EC based on fold expression and p value, but also based on
public database information as subcellular localization, type of
protein, association with cancer or biological factors that theo-
retically would improve their utility as a biomarker such as
protein presence on biological fluids or specificity of expres-
sion in endometrial tissue. The list of the selected candidate
genes included ACAA1, AP1M2, CGN, DDR1, EPS8L2,
FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2,
PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2
and DCN (Table 1).
Uterine aspirates reliably mirror the molecular
alterations found in primary tumors
The next step in setting up the basis for a minimally inva-
sive screening test based on molecular biomarkers to be
applied on uterine aspirates was to verify whether the endo-
metrial aspirate is a reliable surrogate of its primary tumor.
Endometrial aspirates contain fragmented samples of the
uterine cavity content, embedded in blood or mucus. Sam-
ples obtained from hyperplastic or tumoral endometria are
usually very abundant, but those from atrophic endometria
show scant epithelial strips or no endometrial tissue to be
evaluated histologically. We thus compared the expression
levels of the selected candidate genes on a series of nine
paired samples of uterine aspirates and primary tumors
from the same patients (Supporting Information Table 3).
As can be seen in Figure 2, the expression levels of all the
candidate genes demonstrated a high degree of correlation
between the uterine fluids and their corresponding primary
tumors. This data demonstrated that uterine fluids are rep-
resentative of the molecular alterations characterizing the
primary tumors and so could be used to assess biomarkers
for EC.
Table 2. Differential expression of biomarkers (mean RQ) in aspirate samples from patients having endometrial cancer compared to aspirates
from control patients not having endometrial cancer
Gene Mean RQ SEM p value
Global tumor vs. normal Initial-stage tumor vs. normal
AUROC Sensitivity (%) Specificity (%) AUROC Sensitivity (%) Specificity v
ACAA1 1.47 0.48 <0.0001 0.78 88.46 66.67 0.82 91.67 66.67
AP1M2 1.69 0.42 <0.0001 0.83 76.92 75.00 0.80 100.00 54.17
CGN 2.35 1.31 <0.0001 0.85 76.92 87.50 0.78 66.67 87.50
DDR1 0.25 0.20 0.002 0.74 92.31 70.83 0.73 91.67 66.67
EPS8L2 1.52 0.53 0.0167 0.84 80.77 79.17 0.83 100.00 62.50
RASSF7 0.41 0.29 <0.0001 0.81 76.92 87.50 0.80 75.00 87.50
TJP3 1.65 0.56 0.0016 0.81 80.77 79.17 0.77 75.00 83.33
PPFIBP2 1.69 0.66 <0.0001 0.80 92.31 62.50 0.82 91.67 70.83
PPP1R16A 1.34 0.49 <0.0001 0.82 73.08 83.33 0.76 75.00 75.00
IKBKE 2.88 1.62 <0.0001 0.90 92.31 75.00 0.91 100.00 75.00
FASTKD1 1.54 0.50 0.0002 0.83 69.23 87.50 0.84 100.00 58.33
GMIP 2.00 0.65 <0.0001 0.85 84.62 79.17 0.83 91.67 66.67
P2RX4 1.56 0.38 <0.0001 0.80 100.00 58.33 0.77 100.00 58.33
PHKG2 1.54 0.73 0.0094 0.86 92.31 70.83 0.78 83.33 70.83
SIRT6 1.92 0.79 <0.0001 0.84 73.08 95.83 0.75 58.33 95.83
RNF183 1.85 0.77 0.0001 0.88 76.92 95.83 0.92 83.33 95.83
P4HB 3.65 2.37 <0.0001 0.95 100.00 87.50 0.94 100.00 87.50
SOCS2 1.61 0.55 <0.0001 0.93 96.15 75.00 0.93 100.00 75.00
EFEMP2 0.27 0.18 <0.0001 0.88 80.77 87.50 0.94 91.67 87.50
DCN 2.09 0.93 <0.0001 0.81 92.31 70.83 0.80 91.67 62.50
AUROC values for the biomarkers determined from aspirate samples in affected (global: all types and grades of endometrial cancer) and
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Validation of the new EC biomarkers in uterine aspirates
As the results suggested, the group of the 20 selected candi-
date genes could be used to define an increased likelihood of
EC based on their expression levels in samples obtained from
uterine fluid. We thus aimed to address in a further step of
validation whether the selected candidate genes were differen-
tially expressed in endometrial aspirates from EC patients
(n ¼ 26; 21 endometrioid adenocarcinomas and five tumor
samples from different Type II carcinomas), compared to
healthy donors (n ¼ 24; atrophic endometrium, normal
endometrium with polyps from postmenopausal women and
samples from premenopausal women both in secretory phase
and in proliferative phase of the cycle). Again, the series
included representative tumors from all histological type and
grade (Supporting Information Table 4). Hence, RT-qPCR
data were collected for the set of 20 selected candidate genes
and quantified relative to POLR2A levels as a housekeeping
gene. The results clearly confirmed the differential expression
of biomarkers in aspirate samples from patients having EC
compared to aspirates from patients not having EC (Table 2).
The RQ values for the aspirates corresponding to the 26 tu-
mor samples and the 24 samples that were not EC (normal)
are illustrated in a box plot (Fig. 3).
The sensitivity and specificity for each individual gene
represented by the area under the ROC (AUROC) curve
for each gene when comparing the RQ values from the 26
tumor samples and the 24 control samples were also calcu-
lated (Table 2). As can be observed, the markers identified in
these studies have excellent sensitivity and/or specificity for
defining an increased likelihood of EC in minimally invasive
uterine aspirates. More interestingly, the suitability of these
genes as markers for early detection was confirmed when we
focused on initial stages among tumor aspirates (Table 2).
No differences were found when the comparison was per-
formed between histology types, although the limited number
of samples precluded conclusive evaluation. In conclusion,
the AUROC values for these biomarkers indicate that these
markers could have a utility in the diagnosis of EC.
Validation of the new biomarkers at the protein level
We finally sought to analyze and validate at the protein level
the expression of three candidate genes, P4HB, PPP1R16A
and EPS8L2, by immunohistochemistry on ECs. For this, we
constructed TMAs to cover the complete range from normal
tissue to different types and grades of ECs (see Material and
Methods). As shown in Figure 4, TMA immunohistochemis-
try confirmed the differential expression of the three proteins
at the tumoral glands (T) when compared to the normal en-
dometrial glands (n). P4HB, PPP1R16A and EPS8L2 pre-
sented a specific cytoplasmatic expression within the tumoral
cells in all carcinoma histological types and grades and an
absence or faint cytoplasmatic stain within the normal epi-
thelial glands (Fig. 4; upper panels).
Likewise, Western blotting further confirmed the specific dif-
ferential expression of P4HB as the most specific and sensitive
EC marker among candidate genes, in tumor samples compared
to paired normal endometrial tissue from four different patients
(Fig. 4, lower panel). All these results further demonstrate the
suitability of these candidate genes as EC markers.
Discussion
Current methods for detecting EC include pathology assess-
ment on uterine aspirates, hysteroscopy-guided biopsies and
curettage method, which is considered the gold standard but
can cause significant discomfort. In addition, this diagnosis
has only a moderate ability to predict final pathology in EC
Figure 3. Box–Whisker plot for the selected candidates in uterine aspirates from patients diagnosed with endometrial carcinoma (C) and
nonaffected women (N). The horizontal white lines within the boxes denote the medians, and the boxes span the 25th and 75th
percentiles of the distributions. The vertical lines above and below each box indicate the range of the distribution. Outliers defined as 3
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and may require a trained pathologist for interpretation;
therefore, it is not suitable as a general screening tool. Addi-
tional factors should be considered in selecting patients for a
surgical staging procedure.6
Transvaginal ultrasound measuring the thickness of the
endometrium also represents a standard minimally invasive
method for diagnosing EC. In a study of patients having
postmenopausal bleeding, using a cutoff of 4 mm, it was
found that transvaginal ultrasound had 100% sensitivity and
60% specificity.7 In women without vaginal bleeding, the sen-
sitivity of the endometrial thickness measurement was 17%
for a threshold of 6 mm and 33% for a threshold of 5 mm.8
To date, imaging techniques have a role on presurgery
stratification rather than on diagnosis. Magnetic resonance
imaging (MRI) has become an indispensable tool in the
assessment of malignant diseases. In gynecological malignan-
cies, this modality has to assume greater responsibility, par-
ticularly in the evaluation of cervical and ECs. In addition to
conventional imaging, innovative techniques such as dynamic
contrast-enhanced MRI and diffusion-weighted MRI show
promise in offering early assessment of tumor response.9
Concerning PET/PET-computed tomography (CT) in the
management of gynecological malignancies, the promise of
this technique is becoming increasingly evident. 2-Fluoro-2-
deoxy-D-glucose-PET appears to have a potential role in
assessing response to treatment and forecasting prognosis.
With regard to its role in EC, its benefit is particularly
emphasized in the setting of post-therapy surveillance of the
disease, although, in a limited series, it also appears to give
additional information in the pretreatment states. PET may
be of value in detecting the extrauterine lesions that are not
visualized with CT/MRI.10
Figure 4. Specific endometrial carcinoma expression of candidate biomarkers at the protein level. Immunohistochemistry of P4HB, PPP1R16A
and EPS8L2 in representative examples of endometrial carcinoma (upper panels). Specific staining at tumor glands (T) in contrast to faint labeling
in normal glands (n) and stroma (st) in different histological types including endometrioid (1, 3, 4, 5, 6, 7, 8), serous (2) and clear cell (9)
carcinomas. Western blot analysis of P4HB in paired samples including tumor tissue (T) and adjacent normal endometrium (N) from four different
















2442 Minimally invasive endometrial carcinoma biomarkers
Int. J. Cancer: 129, 2435–2444 (2011) VC 2011 UICC
The precise molecular events that occur during the devel-
opment, progression/invasion and formation of metastasis in
EC are largely uncharacterized and are still poorly under-
stood.3 Type I cancers are typically known to have alterations
in PTEN, KRAS2, DNA mismatch repair defects, CTNNB1,
and have near diploid karyotype. Type II cancers typically
have TP53 mutations and ErBB2 overexpression and are
mostly nondiploid.11
A number of studies have examined gene expression profiles
for classifying uterine cancers. Sugiyama et al. reported 45 genes
highly expressed in Type I cancers and 24 highly expressed in
Type II cancers.12 Risinger et al. reported distinct gene expres-
sion profiles among different histologic subtypes of ECs by
microarray analysis, with 191 genes exhibiting greater than two-
fold difference in expression between endometrioid and nonen-
dometrioid ECs.13 In our group, we have identified a number of
genes associated with endometrial carcinogenesis.14 Serum
markers for the detection of uterine cancer have also been
reported in the literature. Yurkovetsky et al. identified that pro-
lactin is a serum biomarker with sensitivity and specificity for
EC.15 They found that serum CA 125, CA 15-3 and CEA are
higher in patients with Stage III disease when compared to Stage
I, and a five-biomarker panel of prolactin, GH, eotaxin, E-selec-
tin and TSH discriminated EC from ovarian and breast cancer.
Nevertheless, none of these potential biomarkers has been vali-
dated nor reached the clinical practice.
All these evidences generate a scenario where (i) there is
a need for less invasive methods of screening for EC, which
are less subjective in interpretation, and (ii) there is a need
for new markers that are useful for the early detection of
EC. Clearly, there is room for improvement in the tools cur-
rently available for screening for EC. In our work, we pres-
ent two main findings: first, the identification and validation
of new potent molecular biomarkers for the detection of EC.
Second, the successful application of these biomarkers to a
minimally invasive uterine fluid representative of the pri-
mary tumor. The result is a minimally invasive and a highly
sensitive and specific method for the identification of EC.
This could be of help for the pathologists as a molecular
precise tool for diagnosing ECs and for the gynecologists for
reducing unnecessary biopsies.
Moreover, the American Cancer Society (ACS) concluded
that there was insufficient evidence to recommend screening
for EC in women at average risk or those who were at an
increased risk because of a history of unopposed estrogen
therapy, tamoxifen therapy, late menopause, nulliparity, infer-
tility or failure to ovulate, obesity, diabetes or hypertension.
The ACS recommends that women at average and increased
risk should be informed about the risks and symptoms (in
particular, unexpected bleeding and spotting) of EC at the
onset of menopause and should be strongly encouraged to im-
mediately report these symptoms to their physician. Women
at very high risk for EC because of (i) known HNPCC genetic
mutation carrier status; (ii) a substantial likelihood of being a
mutation carrier (i.e., a mutation is known to be present in
the family) or (iii) the absence of genetic testing results in
families with a suspected autosomal dominant predisposition
to colon cancer should consider beginning annual testing for
the detection of early EC at age 35 years. The evaluation of en-
dometrial histology with the endometrial biopsy is still the
standard for determining the status of the endometrium.
Women at high risk should be informed that the recommen-
dation for screening is based on expert opinion, and they also
should be informed about potential benefits, risks and limita-
tions of testing for the detection of early EC.16
Among the clinical applications of the molecular bio-
markers that we identified, a test based on our findings could
be appropriate to screening programs in high-risk feminine
populations, as a highly sensitive and specific minimally inva-
sive method for the diagnosis of EC on uterine aspirates. The
high sensitivity and specificity demonstrated by the new identi-
fied biomarkers among uterine aspirates corresponding to ini-
tial stages of ECs further strengthen their potential on early
detection. A clinical study in a large cohort of patients within
several clinical institutions is actually ongoing to evaluate the
validity and clinical applications of this new EC diagnostic test.
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